E-antigen Discovery Leverage Mnemo’s E-antigen discovery capability, combining in silico and wet-lab work to uncover tumor-specific targets for cell therapy, TCEs, ADCs, and vaccines; ideal for pharma looking to access novel targets or de-risk early immuno-oncology programs through licensing or co-development using Mnemo’s EnfiniT platform.

Platform Licensing Platform licensing opportunities around EnfiniT, Mnemo’s integrated drug discovery engine, enabling external partners to accelerate lead discovery for immuno-oncology targets with potential exclusive or non-exclusive licensing arrangements and joint development plans.

CAR-T Enhancement Preclinical CAR-T enhancement evidence from SUV39H1 inactivation suggests a potential strategy for combination therapies; business development could explore research collaborations or co-development to improve CAR-T memory, persistence, and safety profiles.

Academic Partnerships Academic and RHU-aligned collaborations present a pathway for translational studies and access to clinical samples; Mnemo’s hospital-university ecosystem could be leveraged for early target validation and mechanism research with potential joint funding opportunities.

European Partnering Paris-based Mnemo combines early-stage momentum with multi-modality portfolios; strategic alliances with biotechs and pharma could accelerate manufacturing, clinical progression and geographic expansion of immuno-oncology programs.